The Leucine Rich Repeat Containing G Protein Coupled Receptor 5 pipeline drugs market research report outlays comprehensive information on the Leucine Rich Repeat Containing G Protein Coupled Receptor 5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Leucine Rich Repeat Containing G Protein Coupled Receptor 5 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Oncology which include the indications Solid Tumor, and Metastatic Colorectal Cancer. It also reviews key players involved in Leucine Rich Repeat Containing G Protein Coupled Receptor 5 targeted therapeutics development with respective active and dormant or discontinued products.
The Leucine Rich Repeat Containing G Protein Coupled Receptor 5 pipeline targets constitutes close to six molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, and Preclinical stages are 1, 1, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Leucine Rich Repeat Containing G Protein Coupled Receptor 5 overview
Leucine Rich Repeat Containing G Protein-Coupled Receptor 5, abbreviated as LGR5, is a cell surface receptor belonging to the G protein-coupled receptor (GPCR) superfamily. LGR5 is recognized for its critical role in regulating stem cell functions and tissue homeostasis in various organs. The receptor is characterized by the presence of leucine-rich repeats in its extracellular domain, contributing to its ability to interact with specific ligands. LGR5 is widely expressed in various tissues, with notable prominence in stem cell populations. The receptor’s significance lies in its involvement in the Wnt signaling pathway, a crucial molecular pathway implicated in cell proliferation, differentiation, and tissue regeneration. In the absence of Wnt signaling, LGR5 is targeted for ubiquitin-mediated degradation. However, upon activation of the Wnt pathway, LGR5 is stabilized, allowing it to contribute to the regulation of stem cell maintenance and self-renewal. One of the well-studied roles of LGR5 is its association with intestinal stem cells, where it marks a subpopulation of actively dividing, multipotent cells crucial for maintaining the integrity of the intestinal epithelium. Additionally, LGR5 has been implicated in other tissues, such as the hair follicles, liver, and stomach, where it plays a role in tissue regeneration and repair.
For a complete picture of Leucine Rich Repeat Containing G Protein Coupled Receptor 5’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.